Medical services disruption escalates with 27 surgeries canceled
[Editorial] Deepfake risks in election
US unveils new major sanctions package for Russia's war against Ukraine, Navalny's death
[Robert J. Fouser] Turning Seoul’s dead streams into parks
Temple that housed book on Hangeul launches Hangeul awareness group
Lotte taps former Samsung Biologics exec to lead bio businessBy Kan Hyeong-woo
Published : June 10, 2022 - 15:05
Born in 1977, Lee has over two decades of experience in global biologics and the pharmaceuticals industry, including working at the US Department of Health and Human Services and Bristol Myers Squibb. Before he joined Lotte in August, Lee was the head of Samsung Biologics’ drug product business unit.
Lotte Biologics and its new CEO will officially debut at the upcoming Bio International Convention, which is slated to begin Monday in San Diego, according to a Lotte Holdings official.
Lotte Holdings on Thursday announced in a public notice that it has completed the registration of Lotte Biologics’ incorporation with a starting capital of 1 billion won ($790,000).
Last month, Lotte Group said it will invest 2.5 trillion won into expanding its bio businesses over the next 10 years with the goal of becoming among the top 10 largest contract manufacturing and development organizations in the world by 2030.
Lotte acquired Bristol Myers Squibb’s manufacturing facility in East Syracuse, New York, for $160 million, signaling the beginning of the group’s initiatives to enter the bio industry.
Major hospitals experience disruptions as junior doctors' walkout enters 5th day
Parents of 7 first to receive W10m for childbirth in Seoul
FM Cho meets with UNESCO chief in Brazil